The Case For and Against Cannabis Treatment in MS: Where Did the Evidence Stand in 2004?
A review noted that while animal studies and patient reports strongly supported cannabinoids for MS, objective clinical evidence remained lacking, with better-designed studies failing to show improvement on standard measures.
Quick Facts
What This Study Found
The review identified a gap between promising preclinical evidence and disappointing clinical results. Animal models of MS showed clear efficacy for cannabinoids in controlling spasticity, tremor, and clinical disease severity. Patient self-reports and anecdotal evidence also strongly suggested benefit. However, the translation to clinical proof was incomplete.
Only ten published clinical reports involving 78 patients existed at the time, with equivocal results. The somewhat better-designed studies had failed to demonstrate objective improvement on standard measures, even while patients reported subjective benefit. This disconnect between objective and subjective outcomes was a major challenge for the field.
Key Numbers
Ten published clinical reports involving 78 individuals worldwide at the time of review.
How They Did This
This was a narrative review covering the endocannabinoid system, preclinical evidence from animal models, and clinical trial evidence for cannabinoid treatment of MS symptoms.
Why This Research Matters
This review captured the frustrating state of the field in 2004: compelling biological rationale and patient reports, but clinical trial results that did not convincingly demonstrate objective benefit. The honest assessment of this gap helped identify the need for better outcome measures and larger trials.
The Bigger Picture
The objective vs. subjective outcome gap identified here was subsequently addressed by the MUSEC trial and the development of patient-reported outcome measures as primary endpoints. Sativex was eventually approved based on a combination of objective and subjective evidence.
What This Study Doesn't Tell Us
The review was written before the full results of the CAMS trial and other large studies were available. The small number of clinical reports (10, involving only 78 patients) limited the conclusions that could be drawn.
Questions This Raises
- ?Were the objective measures used in early trials (like the Ashworth scale) appropriate for detecting cannabinoid effects?
- ?Has subsequent research resolved the objective-subjective disconnect?
Trust & Context
- Key Stat:
- Only 10 clinical reports with 78 patients worldwide; objective evidence lacking
- Evidence Grade:
- This is a narrative review honestly assessing the gap between preclinical promise and clinical evidence, providing moderate-level evidence through critical synthesis.
- Study Age:
- Published in 2004. The evidence base has grown substantially since, leading to Sativex approval for MS spasticity.
- Original Title:
- Towards cannabis and cannabinoid treatment of multiple sclerosis.
- Published In:
- Drugs of today (Barcelona, Spain : 1998), 40(8), 663-76 (2004)
- Authors:
- Croxford, J Ludovic(4), Miller, Stephen D
- Database ID:
- RTHC-00162
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why was it so hard to prove cannabis works for MS?
The standard measures used in clinical trials (like the Ashworth scale for spasticity) did not seem to capture what patients experienced. Patients reported feeling better, but the clinical scales did not show improvement. This led to a rethinking of how MS outcomes should be measured.
How many clinical studies existed for cannabis in MS in 2004?
Only ten published clinical reports existed worldwide, involving just 78 individuals total. This extremely limited evidence base was a major obstacle to establishing cannabis as a legitimate MS treatment.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-patches-suppositories-topicals-explained
- cannabis-and-endometriosis-thc-pain
- cannabis-and-menstrual-cramps-period-pain
Cite This Study
https://rethinkthc.com/research/RTHC-00162APA
Croxford, J Ludovic; Miller, Stephen D. (2004). Towards cannabis and cannabinoid treatment of multiple sclerosis.. Drugs of today (Barcelona, Spain : 1998), 40(8), 663-76.
MLA
Croxford, J Ludovic, et al. "Towards cannabis and cannabinoid treatment of multiple sclerosis.." Drugs of today (Barcelona, 2004.
RethinkTHC
RethinkTHC Research Database. "Towards cannabis and cannabinoid treatment of multiple scler..." RTHC-00162. Retrieved from https://rethinkthc.com/research/croxford-2004-towards-cannabis-and-cannabinoid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.